Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets

A Multicentered Prospective Cohort Study of Chinese IBD Patients

NCT05386290 ·Status: UNKNOWN

Anti-Tumor Necrosis Factor (TNF) Treatments, Work Productivity and Quality of Life in Crohn's Disease

NCT01860846 ·Status: COMPLETED

Anti-tumor Necrosis Factor in Patients With Ulcerative Colitis in Clinical Remission: to Continue or Not?

NCT03011268 ·Status: COMPLETED ·Phase: NA

Observational, Real World Study Of Inflectra In Patients With Inflammatory Bowel Disease

NCT03801928 ·Status: COMPLETED

A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants

NCT03710486 ·Status: COMPLETED

Impact of Exclusion Diet in Addition to Anti-TNF Therapy in Crohn's Disease and Ulcerative Colitis: a Prospective, Randomized, Double-arm, Open-label Study

NCT06896305 ·Status: RECRUITING ·Phase: NA

Identification of Predictive Biomarkers for Response to Biologic Therapies and Tofacitinib in Inflammatory Bowel Disease

NCT03885713 ·Status: COMPLETED ·Phase: PHASE4

SSAT 054: Non Genetic Factors in the Pathogenesis of IBD in Twins

NCT02383953 ·Status: UNKNOWN

Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess

NCT02856763 ·Status: COMPLETED

Safety and Immunogenicity of a TNFa Kinoid in Patients With Crohn's Disease

NCT00808262 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Personalising Anti-TNF Therapy in Crohns Disease (PANTS)

NCT03088449 ·Status: UNKNOWN

Efficacy and Safety Comparison of Upadacitinib and Vedolizumab in Second-line Treatment for Crohn's Disease

NCT06446219 ·Status: COMPLETED

A Study of Moderate to Severe Inflammatory Bowel Disease, Including Ulcerative Colitis (UC) and Crohn's Disease (CD)

NCT04873700 ·Status: COMPLETED

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

NCT04877990 ·Status: COMPLETED ·Phase: PHASE2

Study of Factors and Mechanisms Influencing the Effects of Treatments in Crohn's Disease

NCT04135027 ·Status: UNKNOWN

The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness

NCT02423512 ·Status: COMPLETED

Comparative Effectiveness of Biologics or Small Molecule Therapies in Inflammatory Bowel Disease (IBD)

NCT04852666 ·Status: COMPLETED

A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)

NCT01369329 ·Status: COMPLETED ·Phase: PHASE3

Safety of Anti-tumor Necrosis Factor (TNF) Monoclonal Antibodies in Inflammatory Bowel Disease

NCT02066272 ·Status: UNKNOWN

Retrospective Observational Comparison Study Between Ustekinumab and Tofacitinib as Third Line Therapy in a Multicenter Cohort of Patients With Refractory Ulcerative Colitis.

NCT05728008 ·Status: COMPLETED

IUS Predicts Upadacitinib Efficacy in Patients With Moderate to Severe Crohn's Disease：a Prospective Study

NCT06573944 ·Status: RECRUITING

Biomarkers of Anti-TNF Treatment in Inflammatory Bowel Disease (IBD)

NCT01971970 ·Status: COMPLETED

A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease

NCT00055523 ·Status: COMPLETED ·Phase: PHASE2

Multi-omics to Predict Responses to Biologics in IBD

NCT05542459 ·Status: UNKNOWN

Long-term Safety and Tolerability Study of Adalimumab in Subjects With Crohn's Disease

NCT00195715 ·Status: COMPLETED ·Phase: PHASE3